133 related articles for article (PubMed ID: 33905391)
21. Treatment of squamous cell carcinoma of the eyelid with imiquimod 5% cream.
Singh M; Singh H; Kakkar N; Zadeng Z; Gupta P
Can J Ophthalmol; 2019 Feb; 54(1):e24-e27. PubMed ID: 30851791
[No Abstract] [Full Text] [Related]
22. Five-Year Results of a Randomized Controlled Trial Comparing Effectiveness of Photodynamic Therapy, Topical Imiquimod, and Topical 5-Fluorouracil in Patients with Superficial Basal Cell Carcinoma.
Jansen MHE; Mosterd K; Arits AHMM; Roozeboom MH; Sommer A; Essers BAB; van Pelt HPA; Quaedvlieg PJF; Steijlen PM; Nelemans PJ; Kelleners-Smeets NWJ
J Invest Dermatol; 2018 Mar; 138(3):527-533. PubMed ID: 29045820
[TBL] [Abstract][Full Text] [Related]
23. An Algorithm for the Management of Residual Head and Neck Melanoma In Situ Using Topical Imiquimod: A Pilot Study.
Tsay C; Kim S; Norwich-Cavanaugh A; Hsia HC; Narayan D
Ann Plast Surg; 2019 Apr; 82(4S Suppl 3):S199-S201. PubMed ID: 30855388
[TBL] [Abstract][Full Text] [Related]
24. A randomized trial of the off-label use of imiquimod, 5%, cream with vs without tazarotene, 0.1%, gel for the treatment of lentigo maligna, followed by conservative staged excisions.
Hyde MA; Hadley ML; Tristani-Firouzi P; Goldgar D; Bowen GM
Arch Dermatol; 2012 May; 148(5):592-6. PubMed ID: 22431716
[TBL] [Abstract][Full Text] [Related]
25. Topical Imiquimod for Lentigo Maligna: Survival Analysis of 103 Cases With 17 Years Follow-up.
Chambers M; Swetter SM; Baker C; Saunders E; Chapman MS
J Drugs Dermatol; 2021 Mar; 20(3):346-348. PubMed ID: 33683087
[TBL] [Abstract][Full Text] [Related]
26. Imiquimod cream 5% for the treatment of arsenic-induced cutaneous neoplasms.
Lonergan CL; McNamara EK; Cordoro KM; Greer KE
Cutis; 2010 Apr; 85(4):199-202. PubMed ID: 20486460
[TBL] [Abstract][Full Text] [Related]
27. [Solar keratosis: from precancerous lesion to pre-invasive squamous cell carcinoma--therapeutic approach with a bioinductive method].
Oster-Schmidt C; Altmeyer P; Markus S
J Dtsch Dermatol Ges; 2003 Oct; 1(10):790-6. PubMed ID: 16281815
[TBL] [Abstract][Full Text] [Related]
28. Successful treatment of two invasive squamous cell carcinomas with topical 5% imiquimod cream in elderly patients.
Tiodorovic-Zivkovic D; Zalaudek I; Longo C; De Pace B; Albertini G; Argenziano G
Eur J Dermatol; 2012; 22(4):579-80. PubMed ID: 22652500
[No Abstract] [Full Text] [Related]
29. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review.
Love WE; Bernhard JD; Bordeaux JS
Arch Dermatol; 2009 Dec; 145(12):1431-8. PubMed ID: 20026854
[TBL] [Abstract][Full Text] [Related]
30. Successful treatment of multifocal pigmented basal cell carcinomas with the application of topical 5% imiquimod cream.
Plachouri KM; Balasis S; Mallioris AF; Koumoundourou D; Georgiou S
Dermatol Ther; 2018 Sep; 31(5):e12685. PubMed ID: 30133929
[TBL] [Abstract][Full Text] [Related]
31. Long-Term Outcomes of Melanoma In Situ Treated With Topical 5% Imiquimod Cream: A Retrospective Review.
Park AJ; Paul J; Chapman MS; Samie FH
Dermatol Surg; 2017 Aug; 43(8):1017-1022. PubMed ID: 28328708
[TBL] [Abstract][Full Text] [Related]
32. Treatment of extramammary Paget disease with topical imiquimod cream: case report and literature review.
Cohen PR; Schulze KE; Tschen JA; Hetherington GW; Nelson BR
South Med J; 2006 Apr; 99(4):396-402. PubMed ID: 16634252
[TBL] [Abstract][Full Text] [Related]
33. Long-Term Follow-Up Results of Topical Imiquimod Treatment in Basal Cell Carcinoma.
Bostanci S; Kocyigit P; Vural S; Heper AO; Botsali A
Dermatol Surg; 2018 Jan; 44(1):36-41. PubMed ID: 29016542
[TBL] [Abstract][Full Text] [Related]
34. Imiquimod for the treatment of Bowen's disease and invasive squamous cell carcinoma.
Nouri K; O'Connell C; Rivas MP
J Drugs Dermatol; 2003 Dec; 2(6):669-73. PubMed ID: 14711149
[TBL] [Abstract][Full Text] [Related]
35. Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients.
Ulrich C; Bichel J; Euvrard S; Guidi B; Proby CM; van de Kerkhof PC; Amerio P; Rønnevig J; Slade HB; Stockfleth E
Br J Dermatol; 2007 Dec; 157 Suppl 2(Suppl 2):25-31. PubMed ID: 18067628
[TBL] [Abstract][Full Text] [Related]
36. Imiquimod: an effective alternative for the treatment of invasive cutaneous squamous cell carcinoma.
Martín-García RF
Dermatol Surg; 2005 Mar; 31(3):371-4. PubMed ID: 15841646
[TBL] [Abstract][Full Text] [Related]
37. A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up.
Krawtchenko N; Roewert-Huber J; Ulrich M; Mann I; Sterry W; Stockfleth E
Br J Dermatol; 2007 Dec; 157 Suppl 2():34-40. PubMed ID: 18067630
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic effect of Imiquimod enhanced ALA-PDT on cutaneous squamous cell carcinoma.
Bhatta AK; Wang P; Keyal U; Zhao Z; Ji J; Zhu L; Wang X; Zhang G
Photodiagnosis Photodyn Ther; 2018 Sep; 23():273-280. PubMed ID: 30030167
[TBL] [Abstract][Full Text] [Related]
39. Topical and intralesional treatment of nonmelanoma skin cancer: efficacy and cost comparisons.
Chitwood K; Etzkorn J; Cohen G
Dermatol Surg; 2013 Sep; 39(9):1306-16. PubMed ID: 23915332
[TBL] [Abstract][Full Text] [Related]
40. An open-label, pilot study examining the efficacy of curettage followed by imiquimod 5% cream for the treatment of primary nodular basal cell carcinoma.
Wu JK; Oh C; Strutton G; Siller G
Australas J Dermatol; 2006 Feb; 47(1):46-8. PubMed ID: 16405483
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
